Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GlaxoSmithKline (GSK) Stock Moves -0.74%: What You Should Know
10:00pm, Thursday, 16'th Jun 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $41.64, marking a -0.74% move from the previous day.
GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know
10:15pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $41.95 in the latest trading session, marking a +1.72% move from the prior day.
COVID-variant booster from Sanofi, GSK shows promising results
09:13pm, Monday, 13'th Jun 2022 MarketWatch
A COVID-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of omicron when given as a booster compared with
Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron
05:29pm, Monday, 13'th Jun 2022 Zacks Investment Research
Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary re
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
01:41pm, Monday, 13'th Jun 2022 Zacks Investment Research
GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the secon
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes
12:45pm, Saturday, 11'th Jun 2022 The Motley Fool
Improving your investing process tends to have high returns.
Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use
12:41pm, Friday, 10'th Jun 2022 Zacks Investment Research
European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.
What Could a Recession Mean for Healthcare Stocks?
03:30pm, Thursday, 09'th Jun 2022 The Motley Fool
It depends on which subsector you're talking about.
GlaxoSmithKline (GSK) Stock Moves -0.11%: What You Should Know
10:00pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $44.20, moving -0.11% from the previous trading session.
Diamond Hill International Fund 2022 Market Commentary
04:03am, Wednesday, 08'th Jun 2022 Seeking Alpha
During Q1 '22, the Diamond Hill International Fund held up better than the Morningstar Global Markets ex-US Index. Click here to read the full fund letter.
GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix
02:13pm, Monday, 06'th Jun 2022 Zacks Investment Research
The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
10:00pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $43.39, marking a +0.81% move from the previous day.
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
01:17pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
Things Are About to Get a Lot More Interesting at Unilever
03:23pm, Wednesday, 01'st Jun 2022 The Motley Fool
A top activist investor sets his sights on shaking things up at the consumer packaged goods giant.
GSK to Boost Vaccine Portfolio With Affinivax Acquisition
03:26pm, Tuesday, 31'st May 2022 Zacks Investment Research
GSK signs an agreement to acquire Affinivax, Inc. for a $2.1 billion upfront payment. The company is looking to boost its vaccine pipeline with this acquisition.
